In a phase 3b randomized clinical trial with open-label extension, bimekizumab demonstrated rapid and sustained improvement in patient-reported outcomes and clinical measures for individuals with moderate to severe PlaquePsoriasis.

By week 4 and through 3 years, a majority of patients reported no itching, skin pain, or scaling, and achieved Dermatology Life Quality Index (DLQI) scores reflecting minimal or no impact on daily life.

Patients switching from secukinumab to bimekizumab at 1 year experienced improvements in perceived symptoms and quality of life comparable to those continuously treated with bimekizumab.

This randomized clinical trial with an open-label extension assesses patient-reported and clinical outcomes among patients with moderate to severe plaque psoriasis treated with bimekizumab.